The role of pharmacodynamic research in the assessment and development of new antibacterial drugs

Biochemical Pharmacology

Volumn 71, Issue 7, 2006, Pages 1057-1065

  Lister, Philip D ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal Models; Antibacterial; Development; IVPM; Pharmacodynamics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERICIDE; BETA LACTAM ANTIBIOTIC; GATIFLOXACIN; LEVOFLOXACIN; PENICILLIN G; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; URANYL NITRATE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG USE; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVIEW; STREPTOCOCCUS INFECTION;

EID: 33644510131     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.10.038     Document Type: Article

References (50)

1. S. Keil, and B. Widemann Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models Antimicrob Agents Chemother 39 1995 1054 1058
2. R. Haag, P. Lexa, and I. Werkhauser Artifacts in dlution pharmacokinetic models caused by adherent bacteria Antimicrob Agents Chemother 29 1986 765 768
3. S.H. Zinner, M. Husson, and J. Klasterksy An artificial capillary in vitro kinetic model of antibacterial activity J Infect Dis 144 1981 583 587
4. J. Blaser, B.B. Stone, and S.H. Zinner Two compartment kinetic model with multiple artificial capillary units J Antimicrob Chemother 15 Suppl A 1985 131 137
5. H. Eagle, R. Fleishman, and M. Levy On the duration of penicillin action in relation to its concentration in the serum J Lab Clin Med 40 1953 122 132
6. H. Eagle, R. Fleishman, and A. Musselman Effect of schedule of administration on the therapeutic efficacy of penicillin Am J Med 9 1950 280 299
7. M.N. Dudley, and D. Griffith Animal models of infection for the study of antibiotic pharmacodynamics C.H. Nightingale T. Murakawa P.G. Ambrose Antimicrobial pharmacodynamics in theory and clinical practice 2002 Marcel Dekker Inc. New York 67 97
8. J. Mordenti Pharmacokinetic scale-up: Accurate prediction of human pharmacokinetic profiles from animal data J Pharm Sci 74 1985 1097 1099
9. D. Andes, and W. Craig In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determination Antimicrob Agents Chemother 42 1998 2375 2379
10. D. Overbosch, C.V. Gulpen, J. Hermans, and H. Mattie The effect of probenicid on the renal tubular excretion of benzylpenicillin Br J Clin Pharm 25 1988 51 58
11. M.N. Dudley, D. Gilbert, T. Longest, and S.H. Zinner Dose ranging of the pharmacodynamics of cefoperazone plus sulbactam in an in vitro model of infection: comparison using a new parameter - area under the survival fraction versus time curve Pharmacotherapy 9 1989 189
12. J. Tisdale, M. Pasko, and J. Mylotte Antipseudomonal activity of simulated infusion of gentamycin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve Antimicrob Agents Chemother 33 1989 9
13. B.J. McGrath, E.M. Bailey, K.C. Lamp, and M.J. Rybak Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model Antimicrob Agents Chemother 36 1992 2741 2746
14. P.D. Lister, A. Pong, S.C. Chartrand, and C.C. Sanders Rationale behind high-dose amoxicillin therapy for otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies Antimicrob Agents Chemother 41 1997 1926 1932
15. G.L. Daikos, G.G. Jackson, V.T. Lolans, and D.M. Livermore Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation J Infect Dis 162 1990 414 420
16. G.L. Daikos, V.T. Lolans, and G.G. Jackson First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use Antimicrob Agents Chemother 35 1991 117 123
17. L.B. Gilleland, H.E. Gilleland, J.A. Gibson, and F.R. Champlin Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa J Med Microbiol 29 1989 41 50
18. P.D. Lister, and C.C. Sanders Pharmacodynamics of levofloxacin and ciprofloxacin against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae J Antimicrob Chemother 43 1999 79 86
19. P.D. Lister, and C.C. Sanders Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model Antimicrob Agents Chemother 43 1999 1118 1123
20. W. Craig, and S. Gudmundsson Postantibiotic-effect V. Lorian Antibiotics in laboratory medicine. 1996 Williams and Wilkins Baltimore 296 329
21. R.F. Parker, and S. Luse The action of penicillin on staphylococcus: further observations on the effect of a short exposure J Bacteriol 56 1948 75 81
22. H. Eagle, and A.D. Musselman The slow recovery of bacterial from the toxic effects of penicillin J Bacteriol 58 1949 475 490
23. I. Odenholt-Tornqvist, E. Löwdin, and O. Cars Pharmacodynamic effects of subinhibitory concentrations of ß-lactam antibiotics in vitro Antimicrob Agents Chemother 35 1991 1834 1839
24. O. Cars, and I. Odenholt-Tornqvist The post-antibiotic sub-MIC effect in vitro and in vivo J Antimicrob Chemother 31 Suppl D 1993 159 166
25. M.A. Sande, O.M. Korzeniowski, G.M. Allegro, R.O. Brennan, O. Zak, and W.M. Scheld Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits: preliminary observations on the postantibiotic effect in vivo Rev Infect Dis 3 1981 98 109
26. W. Craig, J. Redington, and S.C. Ebert Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections J Antimicrob Chemother 27 Suppl C 1991 29 40
27. W. Craig Post-antibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infections in man J Antimicrob Chemother 31 Suppl D 1993 149 158
28. W.M. Scheld Therapy of streptococcal endocarditis: correlation of animal models and clinical studies J Antimicrob Chemother 20 Suppl A 1987 71 85
29. C. Carbon Experimental endocarditis: a review of its relevance to human endocarditis J Antimicrob Chemother 31 Suppl D 1993 71 85
30. R. Finch, D. Schurmann, D. Collins, J. McGivern, H. Bobbaers, and J.L. Izquierdo Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequntial i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pnuemonia requiring initial parenteral treatment Antimicrob Agents Chemother 46 2002 1746 1754
31. W. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 12
32. R.C. Owens, and P.G. Ambrose Pharmacodynamics of quinolones C.H. Nightingale P.G. Ambrose T. Murakawa Antimicrobial pharmacodynamics in theory and clinical practice 2002 Marcel Dekker New York 155 176
33. M.-K. Kim, and D.P. Nicolau Aminoglycoside pharmacodynamics C.H. Nightingale P.G. Ambrose T. Murakawa Antimicrobial pharmacodynamics in theory and clinical practice 2002 Marcel Dekker New York 125 153
34. J. Turnidge Pharmacodynamics and dosing of aminoglycosides Infect Dis Clin North Am 17 2003 503 528
35. G. Drusano, M.-T. Labro, O. Cars, P. Mendes, P. Shah, and F. Sorgel Pharmacokinetics and pharmacodynamics of fluoroquinolones Clin Microbiol Infect 4 Suppl 2 1998 2S27 2S41
36. W. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid Infect Dis Clin North Am 17 2003 479 501
37. W. Craig Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diag Microbiol Infect Dis 22 1995 89 96
38. J.J. McNabb, and K.Q. Bui Beta-lactam pharmacodynamics C.H. Nightingale P.G. Ambrose T. Murakawa Antimicrobial pharmacodynamics in theory and clinical practice 2002 Marcel Dekker New York 99 123
39. A.U. Gerber, W.A. Craig, H.P. Brugger, C. Feller, A.P. Vastola, and J. Brandel Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice J Infect Dis 147 1983 910 917
40. M.N. Dudley Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones Am J Med 91 6A 1991 45S 50S
41. J.T. Smith Awakening the slumbering potential of the 4-quinolone antibacterials Pharm J 233 1984 299 305
42. Thomson Physicians' desk reference 2004 Medical Economics Company Montvale, NJ
43. L.M. Dunbar, M.M. Khashab, J.B. Kahn, N. Zadeikis, J.X. Xiang, and A.M. Tennenberg Efficacy of 750 mg, 5-day levofloxcain in the treatment of community-acquired pneumonia caused by atypical pathogens Curr Med Resp Opin 20 2004 555 563
44. L.M. Dunbar, R.G. Wunderink, and M.P. Habib High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm Clin Infect Dis 37 2003 752 760
45. P.G. Ambrose, S.M. Bhavnani, and R.C. Owens Clinical pharmacodynamics of quinolones Infect Dis Clin North Am 2003 529 543
46. W. Craig Does the dose matter? Clin Infect Dis 33 Suppl 3 2001 S227 S233
47. W. Craig Pharmacokinetics of antibiotics with special emphasis on cephalosporins Clin Microbiol Infect 6 Suppl 3 2000 46 49
48. P. Lister Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae: impact of AUC:MIC ratios on eradication from an in vitro pharmacodynamic model Antimicrob Agents Chemother 46 2002 69 74
49. W. Craig Pharmacodynamics of antimicrobials: general concepts and applications C.H. Nightingale P.G. Ambrose T. Murakawa Antimicrobial pharmacodynamics in theory and clinical practice 2002 Marcel Dekker New York 1 22
50. D. Andes, M.V. Ogtrop, and W. Craig Pharmacodynamic activity of a new oxazolidinone in an animal infection model Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 1998 American Society for Microbiology Washington, DC